spacer
home > pmps > summer 2017 > intriguing injections
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Intriguing Injections

PMPS: What are pre-filled syringes (PFSs) and what are they most commonly used for?

Kevin O’Brien: PFSs, by design, are self-administering drug delivery systems. This home-friendly device offers significant benefits to patients, healthcare professionals and manufacturers compared to traditional ‘vial and syringe’ methods. The majority of medications delivered by PFSs are used for chronic diseases, such as diabetes, rheumatoid arthritis and multiple sclerosis. The healthcare industry is increasingly seeing price pressures that generate a growing need for innovative ways to reduce expenses. Thus, these systems are a cost-saving option.

What advantages do patients receive from using a PFS as opposed to other drug delivery systems?

Ultimately, they receive convenience, bettering their quality of life. PFSs allow medication to be safely administered at home, eliminating travel time and doctor office visits. PFSs are becoming of greater interest among many pharmaceutical manufacturers due to their ease-ofuse, which means that these systems can be offered at a premium price. Overall, a PFS makes self-injection easier, and dosing is much more accurate than the traditional vial and syringe, which, in turn, improves patient compliance and outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kevin O’Brien is Vice President at Siegfried. Before joining the company, he held General Manager positions at Horizon Medical, Surgical Technologies and Pharmacia. Kevin has worked in the medical device and pharma industry since 1986. His background includes both Operations Management and Business Development.
spacer
Kevin O’Brien
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

York Health Economics Consortium offers a new health utilities training course

Cost-utility analysis is a requirement for NICE health technology appraisals and is being increasingly used in other contexts and countries. Health utilities, a crucial component of cost-utility analysis, capture the relative change in health-related quality of life resulting from a treatment. As such, health utility can be a key driver of the cost-effectiveness ratio. Obtaining health utility values that are suitable for your economic evaluation, however, may not always be straight forward.
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 
Industry Events

13th Annual Biomarkers Congress

15-16 February 2018, Manchester Central Convention Complex, Manchester, UK

Oxford Global is proud to present the 13th Annual Biomarkers Congress to be held on 15-16 February 2018, Manchester. The congress covers novel developments in biomarker discovery and validation, translation into the clinic, personalised healthcare, Big data management, clinical diagnostics development. Key therapeutic focus areas include Immuno Oncology, Neuroscience, Respiratory, Metabolic and Cardiovascular Diseases
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement